← Back to Clinical Trials
Recruiting NCT06336174

Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Intracranial Atherosclerosis
Sponsor Anhui Medical University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 100
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2022-11-01
Completion 2025-12-31
Interventions
Aspirin Tablet, Clopidogrel Bisulfate Tablets and AtorvastatinEndovascular therapy,Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this study is to explore the mechanism of cognitive impairment in patients with symptomatic intracranial atherosclerotic stenosis (ICAS), and further plans to explore the impact of different treatment options on cognitive function in symptomatic ICAS patients.

Eligibility Criteria

Inclusion Criteria: * Age between 18 and 80 years * Severe stenosis (≥70%-99%) of atherosclerotic internal carotid artery (C6 segment, C7 segment) or middle cerebral artery (M1 segment) confirmed by digital subtraction angiography (DSA) or at least two of the following non-invasive examinations: magnetic resonance angiography (MRA), computed tomography angiography (CTA), or transcranial Doppler (TCD) * Transient ischemic attack (TIA) or minor stroke (National Institute of Health Stroke Scale \[NIHSS\] score ≤ 4 points) * Right-handed and able to cooperate in neuropsychological tests * At least 14 days post-onset of cerebral infarction or TIA * Signed informed consent Exclusion Criteria: * Other diseases that affect cognitive function, such as cerebral hemorrhage, •Parkinson's disease, neurosyphilis, dementia, tumors, etc. * Right upper limb hemiplegia, aphasia, visual field defects, or visual impairments * More than 50% stenosis of the extracranial internal carotid artery, the vertebra

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}